Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.

Name: Kaimen Rigor review — Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
Item: Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
Rating: 39
Author: Alpha1

Rash BG, Ramdas KN, Agafonova N, Naioti E, McClain-Moss L, Zainul Z, Varnado B, Peterson K, Brown M, Leal T, Kopcho S, Carballosa R, Patel P, Brody M, Herskowitz B, Fuquay A, Rodriguez S, Jacobson AF, Leon R, Pfeffer M, Schwartzbard JB, Botbyl J, Oliva AA Jr, Hare JM

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 1★ (Critical), 2 critical, 2 high issues for “Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03559-0

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/fac83dee-33fa-4bb2-8e17-aec4100e4db3" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/fac83dee-33fa-4bb2-8e17-aec4100e4db3/badge" alt="Kaimen Rigor review — 1★ (Critical), 2 critical, 2 high issues for “Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer&#39;s disease: a randomized controlled phase 2a trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

899d7b0025fe4a532849523500235cea65d8937f9f1c2716993eff6defb5a369

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.

Paper source

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×2−2★
IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 15 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues2 demonstrable

01Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
41.7% does not match the reported count 5/13
“5 (41.7)”
Table 1
02Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
8.3% does not match the reported count 1/11
“1 (8.3)”
Table 1
03Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on a composite score (CADS) that includes left hippocampal volume (a surrogate), and the paper also reports improvements in brain volume and DTI measures (surrogates). The paper does not establish that these surrogates are validated predictors of clinical outcomes, and target engagement at the tested dose is not demonstrated (only a biomarker sTIE2 is mentioned, but not linked to efficacy).
“Laromestrocel improved clinical assessments at 39 weeks compared to placebo, as measured by a composite AD score (secondary end point was met: group 2 versus placebo change: 0.38; 95% CI −0.06–0.82), Montreal cognitive assessment and the Alzheimer’s Disease…”
Find in source
04Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes are small fractions of the normal/reference values (e.g., 48.4% slowing of whole brain atrophy, 61.9% slowing of hippocampal atrophy) and are not anchored to a minimal clinically important difference. The composite score difference of 0.38 is small and the paper itself notes that effect sizes as small as 0.2–0.3 may be considered clinically meaningful, but this is not validated.
“At 39 weeks, Laromestrocel slowed the decline of whole brain volume compared to placebo (n = 10) by 48.4% for all treatment groups combined (groups 2–4: P = 0.005; n = 32) and left hippocampal volume by 61.9% (groups 2–4, P = 0.021; n = 32)”
Find in source

Findings by category

201ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 2a randomized controlled trial. The main methodological strengths are rigorous randomization/blinding, detailed reporting of demographics and ethics, and proportional conclusions. The primary weakness is the vague data/code availability statement, which limits reproducibility.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence required reconciliation. The statistics verification component checked only 3 tests (limited coverage) and found no demonstrable errors; the 2 'inconsistent' results were not listed and thus not treated as errors. The citation check found no retracted or unresolved references.

Numerical inconsistencies

2 findings · worst critical

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 2 reported summary statistics mathematically impossible for the stated N (PERCENT).

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 3 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on AD, anti-amyloid antibody limitations (lecanemab, aducanumab, donanemab), and the rationale for MSC therapy. It acknowledges the limitations of prior work (e.g., ARIAs with anti-amyloid drugs) and builds a logical rationale for laromestrocel. The hypothesis follows from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on AD pathology, limitations of current anti-amyloid therapies, and previous phase 1 data on laromestrocel.

Evidence

paraphrase[Introduction, paragraph 1]

“After many failures of monoclonal antibodies attempting to remove amyloid proteins from the brain, three drugs were approved by the US Food and Drug Administration (FDA) between 2021 and 2024.”

paraphrase[Introduction, paragraph 3]

“Cell-based therapy with mesenchymal stem cells (MSCs) is a particularly attractive treatment candidate as it encompasses provascular, anti-inflammatory, immunomodulatory and tissue repair mechanisms of action, with findings validated in a murine AD model.”

paraphrase[Introduction, paragraph 3]

“We have previously shown in a phase I study that laromestrocel (Lomecel-B) is safe in patients with mild AD and does not cause ARIAs, including in ApoE4 homozygous carriers.”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior work on AD pathology, limitations of current anti-amyloid therapies, and previous phase 1 data on laromestrocel.

Evidence

paraphrase[Introduction, paragraph 1]

“After many failures of monoclonal antibodies attempting to remove amyloid proteins from the brain, three drugs were approved by the US Food and Drug Administration (FDA) between 2021 and 2024.”

paraphrase[Introduction, paragraph 3]

“We have previously shown in a phase I study that laromestrocel (Lomecel-B) is safe in patients with mild AD and does not cause ARIAs, including in ApoE4 homozygous carriers.”

Randomization method (block sizes of four, stratified by sex) and unit (patient) are reported. Blinding is described for all personnel. Power analysis is reported but acknowledges the study was not powered for the secondary endpoint. Inclusion/exclusion criteria are detailed. Outlier handling is not explicitly described but the analysis population (ITT/mITT) is defined. Controls (placebo) are appropriate. Independent replication is not applicable for a single trial.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous with adequate randomization, blinding, and pre-specified endpoints, though the power analysis is underpowered for the secondary endpoint.

Evidence

“Randomization was performed electronically using block sizes of four, equally allocated, with each site receiving separate blocks. Randomization was additionally stratified by sex.”

MethodsFind in source

“All study patients, caregivers and all personnel involved in the conduct and interpretation of the study, including investigators, site personnel and sponsor staff, were blinded to treatment group.”

ResultsFind in source

“The study was not powered to detect a statistically significant difference in CADS.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The trial design is rigorous with adequate randomization, blinding, and pre-specified endpoints, though the power analysis is limited by the small sample size.

Evidence

“Randomization was performed electronically using block sizes of four, equally allocated, with each site receiving separate blocks. Randomization was additionally stratified by sex.”

MethodsFind in source

ResultsFind in source

“The study was not powered to detect a statistically significant difference in CADS.”

Statistical analysisFind in source

Sex is reported for all patients, and both sexes are included, so sex_justified is not applicable. Age, weight, BMI, and health status (AD severity) are reported. Demographics include race, ethnicity, and ApoE status. Species/strain and housing are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are well reported, including sex, age, race, ethnicity, and health status.

Evidence

“with a lower proportion of male (44.9%) versus female (55.1%) patients.”

ResultsFind in source

“Age, years, mean (s.d.) | 76.7 (4.40) | 74.9 (7.51) | 70.5 (7.14) | 74.5 (6.07) | 74.1 (6.65)”

Table 1Find in source

“Eligible patients had a clinical diagnosis of mild AD in accordance with the National Institute of Aging and the Alzheimer’s Association criteria at the time of enrollment.”

MethodsFind in source

PASSReviewer 2· 90% conf

Demographic and baseline characteristics are well reported, including sex, age, race, ethnicity, and health status.

Evidence

“Age, years, mean (s.d.) | 76.7 (4.40) | 74.9 (7.51) | 70.5 (7.14) | 74.5 (6.07) | 74.1 (6.65)”

Table 1Find in source

“with a lower proportion of male (44.9%) versus female (55.1%) patients.”

ResultsFind in source

The study reports IRB approval by Western-Copernicus Group IRB with a date. Informed consent is described as written. Regulatory compliance is implied through FDA IND and 21 CFR 1271 for cell products. All applicable criteria are adequate.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are clearly documented with a named IRB, informed consent, and regulatory compliance.

Evidence

“Institutional Review Board (IRB) approval was granted by Western-Copernicus Group Institutional Review Board (WCG IRB) on 24 November 2021.”

MethodsFind in source

“All patients provided written consent on the Western IRB-approved protocol.”

MethodsFind in source

“All bone-marrow collections are regulated under 21 CFR 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are clearly documented with a named IRB, informed consent, and regulatory compliance.

Evidence

“Institutional Review Board (IRB) approval was granted by Western-Copernicus Group Institutional Review Board (WCG IRB) on 24 November 2021.”

MethodsFind in source

“All patients provided written consent on the Western IRB-approved protocol.”

MethodsFind in source

“All bone-marrow collections are regulated under 21 CFR 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).”

MethodsFind in source

Laromestrocel is described with manufacturing details, donor characteristics, and quality control. Antibodies for flow cytometry are identified with catalog numbers and clones. Software (SAS, FlowJo, etc.) is identified. Cell line authentication and mycoplasma testing are not applicable as this is a human trial, but mycoplasma testing is mentioned for the product.

Sub-criteria

mycoplasma testingADEQUATE

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedADEQUATE

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (laromestrocel) is thoroughly described, and antibodies and software used in ancillary assays are identified.

Evidence

paraphrase[Methods, Laromestrocel and placebo sourcing and manufacturing]

“Laromestrocel is an investigational allogeneic adult human MSC therapy, consisting of a suspension of human bone-marrow-derived MSCs.”

“CD105 PE (cat. no. 560839, clone 266, lots 9155633 and 8137932, 5 μl)”

MethodsFind in source

“Laromestrocel must be negative for Mycoplasma”

MethodsFind in source

PASSReviewer 2· 85% conf

The investigational product (laromestrocel) is well characterized, and key reagents and software are identified.

Evidence

“CD105 PE (cat. no. 560839, clone 266, lots 9155633 and 8137932, 5 μl)”

MethodsFind in source

“Laromestrocel must be negative for Mycoplasma”

MethodsFind in source

“All statistical analyses were conducted using SAS software (v.9.4).”

Statistical analysisFind in source

Tests are named (MMRM, Clopper-Pearson, Pearson correlation). Assumptions are not explicitly verified but standard methods are used. Exact p-values are reported for many outcomes, but some are reported as thresholds (e.g., P < 0.1). Effect sizes with CIs are reported for the primary and secondary endpoints. Software (SAS v.9.4) is identified. Data presentation includes per-group n and error bars. Mathematical plausibility checks were not possible for most statistics due to lack of raw data.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs reported; however, some p-values are reported as thresholds.

Evidence

“Change from baseline in CADS was statistically analyzed with an MMRM analysis.”

Statistical analysisFind in source

“group 2 ( n = 11) versus placebo ( n = 10) difference 0.38, 95% CI −0.06–0.82; P = 0.091”

ResultsFind in source

“pre-specified P < 0.1 as a positive outcome due to a small sample size”

ResultsFind in source

PASSReviewer 2· 80% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs, though some p-values are reported as thresholds.

Evidence

“Change from baseline in CADS was statistically analyzed with an MMRM analysis.”

Statistical analysisFind in source

“group 2 ( n = 11) versus placebo ( n = 10) difference 0.38, 95% CI −0.06–0.82; P = 0.091”

ResultsFind in source

“if the two-sided P value for the difference was <0.1, then the difference was considered statistically significant”

Statistical analysisFind in source

The data availability statement says data may be shared under a data-use agreement for IRB-approved research, but does not specify a platform or timeframe. Code availability states SAS code is on file and can be made available under a code use agreement, but no repository is provided. No accession numbers are given.

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability statement is present but vague, and code is not publicly shared.

Evidence

“All requests for data access should be sent to the corresponding authors, B.G.R. or J.M.H. The minimum dataset, without individual patient data, used for the primary, secondary and exploratory conclusions, may be shared under a data-use agreement for IRB-approved research.”

Data availabilityFind in source

“SAS code for the minimum dataset is on file and can be made available under a code use agreement for IRB-approved research.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data availability is stated but vague, and code is not publicly shared, though the trial protocol is available on request.

Evidence

Data availabilityFind in source

“SAS code for the minimum dataset is on file and can be made available under a code use agreement for IRB-approved research.”

Data availabilityFind in source

Methods are detailed enough for replication. Trial registration number is provided. Reporting guideline is not explicitly mentioned but the paper follows CONSORT-like structure. All outcomes are reported, including negative results. Limitations are discussed. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with detailed methods, trial registration, limitations, and proportional conclusions.

Evidence

“ClinicalTrials.gov registration: NCT05233774”

AbstractFind in source

“This study had limitations that warrant mentioning. First, there was a relatively small sample size with a high proportion of patients of Hispanic ethnicity and some variables such as patient education level were not ascertained.”

DiscussionFind in source

“This trial was fully funded by Longeveron.”

AcknowledgementsFind in source

PASSReviewer 2· 85% conf

The manuscript is transparent with trial registration, detailed methods, and discussion of limitations, though no reporting guideline is explicitly mentioned.

Evidence

“ClinicalTrials.gov registration: NCT05233774”

AbstractFind in source

DiscussionFind in source

“This trial was fully funded by Longeveron.”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 66 references by DOI: 66 verified.

2 data/code links checked; 2 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, grammar.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and generally trustworthy, but an informed reader should weigh the limited statistical verification coverage and the vague data/code availability. No erratum is warranted based on the evidence; however, the authors should consider clarifying the data-sharing mechanism and reporting exact p-values to improve transparency.

1.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 41.7% does not match the reported count 5/13
Demonstrable critical failure — blocks the verdict from passing.
2.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 8.3% does not match the reported count 1/11
Demonstrable critical failure — blocks the verdict from passing.
3.
HIGHdata code
In the Data availability section, specify a concrete data-sharing mechanism (e.g., a named repository like Vivli or YODA, or a data-access committee) with conditions and a timeline for access.
The current 'available on request' statement is vague and does not meet modern reproducibility expectations.
4.
HIGHdata code
In the Code availability section, deposit the SAS analysis code in a public repository (e.g., GitHub, Zenodo) with a DOI, or provide a detailed code description.
Sharing code is essential for reproducibility and is currently only available on request.
5.
MEDIUMreporting
In the Methods or a reporting summary, explicitly state adherence to a reporting guideline such as CONSORT.
Explicitly naming the reporting guideline improves transparency and reader confidence.
6.
MEDIUMstatistics
In the Statistical analysis section, report exact p-values for all outcomes instead of thresholds like 'P < 0.1' where possible.
Exact p-values allow readers to assess evidence strength more precisely.
7.
MEDIUMstatistics
In the Statistical analysis section, describe how outliers were handled and clarify missing data imputation methods.
Outlier handling and missing data methods are currently not described, which is a reporting gap.
8.
MEDIUMstatistics
In the Statistical analysis section, add a statement on assumptions verification (e.g., normality, homogeneity of variance) or justify why they are not needed.
Assumption verification is not explicitly reported, which is a common reviewer concern.
9.
MEDIUMreporting
In the Abstract and Results, reconcile the group 2 sample size (n=13 in abstract vs n=12 in mITT table vs n=11 in secondary analysis) and clarify the reasons for each discrepancy.
Inconsistent sample sizes across sections could confuse readers and undermine trust.
10.
MEDIUMreporting
In the Results, clarify that the reported difference (e.g., 0.38) refers to the change from baseline in CADS score.
The current phrasing is ambiguous about what the difference represents.
11.
LOWcopyedit
In the Abstract, ensure consistent use of 'million' vs 'M' notation for cell doses.
Inconsistent notation is a minor copyedit issue that could be confusing.
12.
LOWcopyedit
In the Discussion, rephrase the sentence about laromestrocel's mechanism for clarity.
Minor grammatical issue that affects readability.
13.
LOWreporting
In the Methods, clarify whether the power calculation was post-hoc and describe the basis for the 50% slowing assumption.
The power calculation description is confusing and could be misinterpreted.

Full text (69,534 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03559-0

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/fac83dee-33fa-4bb2-8e17-aec4100e4db3" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/fac83dee-33fa-4bb2-8e17-aec4100e4db3/badge" alt="Kaimen Rigor review — 1★ (Critical), 2 critical, 2 high issues for “Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer&#39;s disease: a randomized controlled phase 2a trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

899d7b0025fe4a532849523500235cea65d8937f9f1c2716993eff6defb5a369

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×2−2★
IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 15 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues2 demonstrable

01Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
41.7% does not match the reported count 5/13
“5 (41.7)”
Table 1
02Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
8.3% does not match the reported count 1/11
“1 (8.3)”
Table 1
03Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on a composite score (CADS) that includes left hippocampal volume (a surrogate), and the paper also reports improvements in brain volume and DTI measures (surrogates). The paper does not establish that these surrogates are validated predictors of clinical outcomes, and target engagement at the tested dose is not demonstrated (only a biomarker sTIE2 is mentioned, but not linked to efficacy).
“Laromestrocel improved clinical assessments at 39 weeks compared to placebo, as measured by a composite AD score (secondary end point was met: group 2 versus placebo change: 0.38; 95% CI −0.06–0.82), Montreal cognitive assessment and the Alzheimer’s Disease…”
Find in source
04Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes are small fractions of the normal/reference values (e.g., 48.4% slowing of whole brain atrophy, 61.9% slowing of hippocampal atrophy) and are not anchored to a minimal clinically important difference. The composite score difference of 0.38 is small and the paper itself notes that effect sizes as small as 0.2–0.3 may be considered clinically meaningful, but this is not validated.
“At 39 weeks, Laromestrocel slowed the decline of whole brain volume compared to placebo (n = 10) by 48.4% for all treatment groups combined (groups 2–4: P = 0.005; n = 32) and left hippocampal volume by 61.9% (groups 2–4, P = 0.021; n = 32)”
Find in source

Findings by category

201ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

2 findings · worst critical

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 2 reported summary statistics mathematically impossible for the stated N (PERCENT).

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 3 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on AD pathology, limitations of current anti-amyloid therapies, and previous phase 1 data on laromestrocel.

Evidence

paraphrase[Introduction, paragraph 1]

“After many failures of monoclonal antibodies attempting to remove amyloid proteins from the brain, three drugs were approved by the US Food and Drug Administration (FDA) between 2021 and 2024.”

paraphrase[Introduction, paragraph 3]

“We have previously shown in a phase I study that laromestrocel (Lomecel-B) is safe in patients with mild AD and does not cause ARIAs, including in ApoE4 homozygous carriers.”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior work on AD pathology, limitations of current anti-amyloid therapies, and previous phase 1 data on laromestrocel.

Evidence

paraphrase[Introduction, paragraph 1]

“After many failures of monoclonal antibodies attempting to remove amyloid proteins from the brain, three drugs were approved by the US Food and Drug Administration (FDA) between 2021 and 2024.”

paraphrase[Introduction, paragraph 3]

“We have previously shown in a phase I study that laromestrocel (Lomecel-B) is safe in patients with mild AD and does not cause ARIAs, including in ApoE4 homozygous carriers.”

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous with adequate randomization, blinding, and pre-specified endpoints, though the power analysis is underpowered for the secondary endpoint.

Evidence

“Randomization was performed electronically using block sizes of four, equally allocated, with each site receiving separate blocks. Randomization was additionally stratified by sex.”

MethodsFind in source

ResultsFind in source

“The study was not powered to detect a statistically significant difference in CADS.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The trial design is rigorous with adequate randomization, blinding, and pre-specified endpoints, though the power analysis is limited by the small sample size.

Evidence

“Randomization was performed electronically using block sizes of four, equally allocated, with each site receiving separate blocks. Randomization was additionally stratified by sex.”

MethodsFind in source

ResultsFind in source

“The study was not powered to detect a statistically significant difference in CADS.”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are well reported, including sex, age, race, ethnicity, and health status.

Evidence

“with a lower proportion of male (44.9%) versus female (55.1%) patients.”

ResultsFind in source

“Age, years, mean (s.d.) | 76.7 (4.40) | 74.9 (7.51) | 70.5 (7.14) | 74.5 (6.07) | 74.1 (6.65)”

Table 1Find in source

“Eligible patients had a clinical diagnosis of mild AD in accordance with the National Institute of Aging and the Alzheimer’s Association criteria at the time of enrollment.”

MethodsFind in source

PASSReviewer 2· 90% conf

Demographic and baseline characteristics are well reported, including sex, age, race, ethnicity, and health status.

Evidence

“Age, years, mean (s.d.) | 76.7 (4.40) | 74.9 (7.51) | 70.5 (7.14) | 74.5 (6.07) | 74.1 (6.65)”

Table 1Find in source

“with a lower proportion of male (44.9%) versus female (55.1%) patients.”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are clearly documented with a named IRB, informed consent, and regulatory compliance.

Evidence

“Institutional Review Board (IRB) approval was granted by Western-Copernicus Group Institutional Review Board (WCG IRB) on 24 November 2021.”

MethodsFind in source

“All patients provided written consent on the Western IRB-approved protocol.”

MethodsFind in source

“All bone-marrow collections are regulated under 21 CFR 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are clearly documented with a named IRB, informed consent, and regulatory compliance.

Evidence

“Institutional Review Board (IRB) approval was granted by Western-Copernicus Group Institutional Review Board (WCG IRB) on 24 November 2021.”

MethodsFind in source

“All patients provided written consent on the Western IRB-approved protocol.”

MethodsFind in source

“All bone-marrow collections are regulated under 21 CFR 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).”

MethodsFind in source

Sub-criteria

mycoplasma testingADEQUATE

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedADEQUATE

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (laromestrocel) is thoroughly described, and antibodies and software used in ancillary assays are identified.

Evidence

paraphrase[Methods, Laromestrocel and placebo sourcing and manufacturing]

“Laromestrocel is an investigational allogeneic adult human MSC therapy, consisting of a suspension of human bone-marrow-derived MSCs.”

“CD105 PE (cat. no. 560839, clone 266, lots 9155633 and 8137932, 5 μl)”

MethodsFind in source

“Laromestrocel must be negative for Mycoplasma”

MethodsFind in source

PASSReviewer 2· 85% conf

The investigational product (laromestrocel) is well characterized, and key reagents and software are identified.

Evidence

“CD105 PE (cat. no. 560839, clone 266, lots 9155633 and 8137932, 5 μl)”

MethodsFind in source

“Laromestrocel must be negative for Mycoplasma”

MethodsFind in source

“All statistical analyses were conducted using SAS software (v.9.4).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs reported; however, some p-values are reported as thresholds.

Evidence

“Change from baseline in CADS was statistically analyzed with an MMRM analysis.”

Statistical analysisFind in source

“group 2 ( n = 11) versus placebo ( n = 10) difference 0.38, 95% CI −0.06–0.82; P = 0.091”

ResultsFind in source

“pre-specified P < 0.1 as a positive outcome due to a small sample size”

ResultsFind in source

PASSReviewer 2· 80% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs, though some p-values are reported as thresholds.

Evidence

“Change from baseline in CADS was statistically analyzed with an MMRM analysis.”

Statistical analysisFind in source

“group 2 ( n = 11) versus placebo ( n = 10) difference 0.38, 95% CI −0.06–0.82; P = 0.091”

ResultsFind in source

“if the two-sided P value for the difference was <0.1, then the difference was considered statistically significant”

Statistical analysisFind in source

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability statement is present but vague, and code is not publicly shared.

Evidence

Data availabilityFind in source

“SAS code for the minimum dataset is on file and can be made available under a code use agreement for IRB-approved research.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data availability is stated but vague, and code is not publicly shared, though the trial protocol is available on request.

Evidence

Data availabilityFind in source

“SAS code for the minimum dataset is on file and can be made available under a code use agreement for IRB-approved research.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with detailed methods, trial registration, limitations, and proportional conclusions.

Evidence

“ClinicalTrials.gov registration: NCT05233774”

AbstractFind in source

DiscussionFind in source

“This trial was fully funded by Longeveron.”

AcknowledgementsFind in source

PASSReviewer 2· 85% conf

The manuscript is transparent with trial registration, detailed methods, and discussion of limitations, though no reporting guideline is explicitly mentioned.

Evidence

“ClinicalTrials.gov registration: NCT05233774”

AbstractFind in source

DiscussionFind in source

“This trial was fully funded by Longeveron.”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 66 references by DOI: 66 verified.

2 data/code links checked; 2 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, grammar.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 41.7% does not match the reported count 5/13
Demonstrable critical failure — blocks the verdict from passing.
2.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 8.3% does not match the reported count 1/11
Demonstrable critical failure — blocks the verdict from passing.
3.
HIGHdata code
In the Data availability section, specify a concrete data-sharing mechanism (e.g., a named repository like Vivli or YODA, or a data-access committee) with conditions and a timeline for access.
The current 'available on request' statement is vague and does not meet modern reproducibility expectations.
4.
HIGHdata code
In the Code availability section, deposit the SAS analysis code in a public repository (e.g., GitHub, Zenodo) with a DOI, or provide a detailed code description.
Sharing code is essential for reproducibility and is currently only available on request.
5.
MEDIUMreporting
In the Methods or a reporting summary, explicitly state adherence to a reporting guideline such as CONSORT.
Explicitly naming the reporting guideline improves transparency and reader confidence.
6.
MEDIUMstatistics
In the Statistical analysis section, report exact p-values for all outcomes instead of thresholds like 'P < 0.1' where possible.
Exact p-values allow readers to assess evidence strength more precisely.
7.
MEDIUMstatistics
In the Statistical analysis section, describe how outliers were handled and clarify missing data imputation methods.
Outlier handling and missing data methods are currently not described, which is a reporting gap.
8.
MEDIUMstatistics
In the Statistical analysis section, add a statement on assumptions verification (e.g., normality, homogeneity of variance) or justify why they are not needed.
Assumption verification is not explicitly reported, which is a common reviewer concern.
9.
MEDIUMreporting
In the Abstract and Results, reconcile the group 2 sample size (n=13 in abstract vs n=12 in mITT table vs n=11 in secondary analysis) and clarify the reasons for each discrepancy.
Inconsistent sample sizes across sections could confuse readers and undermine trust.
10.
MEDIUMreporting
In the Results, clarify that the reported difference (e.g., 0.38) refers to the change from baseline in CADS score.
The current phrasing is ambiguous about what the difference represents.
11.
LOWcopyedit
In the Abstract, ensure consistent use of 'million' vs 'M' notation for cell doses.
Inconsistent notation is a minor copyedit issue that could be confusing.
12.
LOWcopyedit
In the Discussion, rephrase the sentence about laromestrocel's mechanism for clarity.
Minor grammatical issue that affects readability.
13.
LOWreporting
In the Methods, clarify whether the power calculation was post-hoc and describe the basis for the 50% slowing assumption.
The power calculation description is confusing and could be misinterpreted.

Full text (69,534 chars)Analyzed: Aug 15, 2026